Market Overview

UPDATE: Sterne Agee Reiterates On Intuitive Surgical Ahead Of Advisory Committee

Share:
Related ISRG
A New Automation ETF For Traders Who Haven't Yet Been Replaced By Robots
Benzinga's Daily Biotech Pulse: vTv Swoons On Failed Alzheimer's Trial, Regenxbio Gets FDA Fast Track For RGX-111

In a report published Wednesday, Sterne Agee analyst Gregory P. Chodaczek reiterated a Neutral rating on Intuitive Surgical (NASDAQ: ISRG), and raised the price target from $380.00 to $400.00.

In the report, Sterne Agee noted, “The FDA will convene a Medical Device Advisory Committee July 10-11 based on its previous safety advisory discouraging doctors from using power morcellators to remove fibroids. We believe this outcome will move from discouragement to an FDA requirement of a ‘boxed warning' related to the risk of cancer spread using power morcellation. Although we believe this warning will negatively affect Intuitive Surgical, we maintain our Neutral rating with a new price target of $400.00.”

Intuitive Surgical closed on Tuesday at $377.60.

Latest Ratings for ISRG

DateFirmActionFromTo
Jun 2018Morgan StanleyMaintainsOverweightOverweight
Apr 2018Bank of AmericaMaintainsBuyBuy
Apr 2018Canaccord GenuityMaintainsHoldHold

View More Analyst Ratings for ISRG
View the Latest Analyst Ratings

Posted-In: Gregory P. Chodaczek Sterne AgeeAnalyst Color Price Target Analyst Ratings

 

Related Articles (ISRG)

View Comments and Join the Discussion!